<p>Recursion Pharmaceuticals（納斯達克代碼：RXRX - 獲取免費報告）於週三公佈了其季度財報。公司報告本季度每股收益（EPS）為（$0.22），超出市場共識預期的（$0.30）$0.08，FiscalAI 報道。Recursion Pharmaceuticals 的淨利潤率為負 863.37%，股本回報率為負 63.98%。該公司本季度的收入為 647 萬美元，而分析師預期為 1578 萬美元。在去年同期，公司每股收益為（$0.50）。公司的收入同比下降了 56.8%。</p>
<ul>
<li>2 個理由説明 Absci 可能是 AI 生物技術的未來，以及 1 個風險</li>
</ul>
<p>以下是 Recursion Pharmaceuticals 電話會議的關鍵要點：</p>
<ul>
<li><strong>REC-4881：</strong> 公司報告的 FAP 臨牀概念驗證顯示，前癌性息肉顯著減少，且反應持久，正在與 FDA 進行持續溝通以定義潛在的註冊路徑。</li>
<li><strong>REC-1245（RBM39 降解劑）：</strong> 來自 16 名患者的早期 DAHLIA I 期數據報告沒有劑量限制毒性，PD 確認的靶點參與和 PK 支持每日給藥，預計在下半年將有更多劑量遞增和更全面的 PK/PD 結果。</li>
<li><strong>REC-4539（LSD1 抑制劑）：</strong> 第一名患者在 I 期中接受了該分子的給藥，旨在降低血小板減少症風險，並且能夠穿透大腦；初步的 PK 和安全性數據預計在 2027 年下半年發佈。</li>
<li>平台和模型的進展（TxPert，TxFM）以及公司報告的效率聲明——例如，超過 50PB 的多模態數據，合成化合物減少約 90%，開發候選藥物的進展速度約為 2 倍——正在被應用，但仍需通過未來的結果進行獨立驗證。</li>
<li>財務狀況：現金 665 百萬美元，預計資金可持續到 2028 年初，運營費用同比減少 30%，2026 年現金運營費用指導低於 390 百萬美元，管理層表示這將支持近期里程碑而無需額外融資。</li>
</ul>
<h2>Recursion Pharmaceuticals 股票上漲 1.3%</h2>
<p>納斯達克 RXRX 週三上漲 0.05 美元，達到 3.42 美元。該公司交易了 14,705,881 股，較其平均交易量 16,692,518 股有所減少。公司的市值為 18 億美元，市盈率為-2.31，貝塔係數為 1.05。Recursion Pharmaceuticals 的 12 個月低點為 2.80 美元，12 個月高點為 7.18 美元。該股票的 50 日移動平均為 3.40 美元，200 日移動平均為 4.16 美元。公司的流動比率為 5.50，速動比率為 5.50，債務與股本比率為 0.01。</p>
<h2>分析師評級上調與下調</h2>
<ul>
<li>這些是 NVIDIA 13F 投資組合中唯一的 6 只股票</li>
</ul>
<p>多家研究公司最近對 RXRX 發表了評論。華爾街 Zen 在 3 月 28 日的研究報告中將 Recursion Pharmaceuticals 的股票評級從 “持有” 下調至 “賣出”。Needham &amp; Company LLC 在 2 月 26 日的研究報告中重申了 “買入” 評級，並對 Recursion Pharmaceuticals 的股票設定了 8.00 美元的目標價。Weiss Ratings 在 4 月 21 日的研究報告中重申了 Recursion Pharmaceuticals 的 “賣出（d-）” 評級。摩根大通在 4 月 30 日的研究報告中將 Recursion Pharmaceuticals 的目標價從 11.00 美元下調至 10.00 美元，並對該股票設定了 “增持” 評級。最後，美國銀行在 2 月 25 日的研究報告中將 Recursion Pharmaceuticals 的目標價從 7.00 美元下調至 6.00 美元，並對該股票設定了 “中性” 評級。兩位股票研究分析師對該股票給予了 “買入” 評級，兩位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat，Recursion Pharmaceuticals 目前的共識評級為 “持有”，共識目標價為 9.20 美元。</p>
<p><strong>獲取我們關於 Recursion Pharmaceuticals 的最新報告</strong></p>
<h2>內部人員買賣</h2>
<ul>
<li>突然上升：Recursion Pharmaceuticals 是 NVIDIA 的 AI 最愛嗎？</li>
</ul>
<p>在相關消息中，董事 Blake Borgeson 於 4 月 7 日星期二出售了 30,000 股該股票，交易價格為每股 3.10 美元，總交易額為 93,000.00 美元。交易後，該董事直接持有公司股票 6,229,863 股，價值 19,312,575.30 美元。這代表其持股比例減少了 0.48%。該交易已在證券交易委員會的法律文件中披露，可通過 SEC 網站訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，首席財務官 Ben R. Taylor 於 2 月 18 日星期三出售了 13,426 股該股票，交易價格為每股 3.08 美元，總交易額為 41,352.08 美元。交易後，首席財務官直接持有公司 1,195,349 股，價值約 3,681,674.92 美元。這代表其持股比例減少了 1.11%。該交易的披露信息可在 SEC 文件中找到。在過去 90 天內，內部人員共出售了 79,680 股公司股票，價值 256,121 美元。8.43% 的股票由公司內部人員持有。</p>
<h2>機構資金流入與流出</h2>
<p>幾家機構投資者最近買賣了 RXRX 的股票。State Street Corp 在第四季度將其在 Recursion Pharmaceuticals 的持股增加了 38.7%。State Street Corp 目前擁有 25,333,888 股該公司的股票，價值 103,616,000 美元，此前在上個季度又購買了 7,064,963 股。ARK Investment Management LLC 在第四季度將其在 Recursion Pharmaceuticals 的持股增加了 11.2%。ARK Investment Management LLC 目前擁有 37,316,856 股該公司的股票，價值 152,626,000 美元，此前在此期間又購買了 3,771,357 股。Millennium Management LLC 在第四季度購買了 Recursion Pharmaceuticals 的新頭寸，價值約 6,118,000 美元。Geode Capital Management LLC 在第四季度將其在 Recursion Pharmaceuticals 的持股增加了 13.6%。Geode Capital Management LLC 目前擁有 10,934,252 股該公司的股票，價值 44,731,000 美元，此前在此期間又購買了 1,310,695 股。最後，Two Sigma Investments LP 在第三季度將其在 Recursion Pharmaceuticals 的持股增加了 109.9%。Two Sigma Investments LP 目前擁有 2,450,805 股該公司的股票，價值 11,960,000 美元，此前在此期間又收購了 1,282,992 股。機構投資者和對沖基金持有該公司 89.06% 的股票。</p>
<h2>Recursion Pharmaceuticals 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Recursion Pharmaceuticals, Inc NASDAQ: RXRX 是一家生物製藥公司，結合了先進的自動化、人工智能和高通量生物學，以發現和開發新型治療藥物。該公司的專有平台將深度學習算法與大規模細胞成像和化學生物學相結合，使得能夠快速識別各種適應症的潛在藥物候選者。通過自動化複雜的實驗室工作流程並利用計算模型，Recursion 旨在加速藥物發現過程並擴大可以解決的靶點範圍。</p>
<p>Recursion 提供的核心是其數字生物學平台，該平台在不同的化學和遺傳干擾下捕獲數十億個細胞圖像。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們認為比 Recursion Pharmaceuticals 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlhSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlhSWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Recursion Pharmaceuticals 嗎？</h2>
<p>在你考慮 Recursion Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Recursion Pharmaceuticals 並不在名單上。</p>
<p>雖然 Recursion Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

RXRX

標普全球醫療股指數 ETF - iShares

動態生物技術與基因組 ETF - Invesco

<p>Recursion Pharmaceuticals（納斯達克代碼：RXRX）報告的季度每股收益為（$0.22），超出預期的（$0.30）$0.08。該公司的收入為 647 萬美元，顯著低於預期的 1578 萬美元，同比下降 56.8%。儘管淨利潤率為負 863.37%，股本回報率為負 63.98%，但該公司仍保持強勁的現金儲備，達到 6.65 億美元，預計可支持運營至 2028 年初。股價上漲 1.3%，至 3.42 美元，分析師評級不一，市場共識目標價為 9.20 美元</p>

<p>Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.08, FiscalAI reports. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The firm had revenue of $6.47 million during the quarter, compared to analysts' expectations of $15.78 million. During the same period in the prior year, the company posted ($0.50) EPS. The company's revenue was down 56.8% on a year-over-year basis.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals（納斯達克代碼：RXRX - 獲取免費報告）於週三公佈了其季度財報。公司報告本季度每股收益（EPS）為（$0.22），超出市場共識預期的（$0.30）$0.08，FiscalAI 報道。Recursion Pharmaceuticals 的淨利潤率為負 863.37%，股本回報率為負 63.98%。該公司本季度的收入為 647 萬美元，而分析師預期為 1578 萬美元。在去年同期，公司每股收益為（$0.50）。公司的收入同比下降了 56.8%。</p>
</div><ul>
<li>2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk</li>
</ul>
<div class="lb-trans"><ul>
<li>2 個理由説明 Absci 可能是 AI 生物技術的未來，以及 1 個風險</li>
</ul>
</div><p>Here are the key takeaways from Recursion Pharmaceuticals' conference call:</p>
<div class="lb-trans"><p>以下是 Recursion Pharmaceuticals 電話會議的關鍵要點：</p>
</div><ul>
<li><strong>REC-4881:</strong> Company-reported clinical proof-of-concept in FAP showing significant reductions in precancerous polyps with durable responses, and ongoing FDA engagement to define a potential registrational path.</li>
<li><strong>REC-1245 (RBM39 degrader):</strong> Early DAHLIA Phase I data from 16 patients report no dose-limiting toxicities, PD-confirmed target engagement and PK supportive of daily dosing, with more dose-escalation and fuller PK/PD readouts expected in H2.</li>
<li><strong>REC-4539 (LSD1 inhibitor):</strong> First patient dosed in Phase I for a molecule designed to reduce thrombocytopenia risk and that is brain-penetrant; initial PK and safety data are expected in H2 2027.</li>
<li>Platform and model advances (TxPert, TxFM) and company-reported efficiency claims — e.g., &gt;50 PB of multimodal data, ~90% fewer compounds synthesized and ~2x faster progress to development candidates — are being deployed but remain company-reported metrics to be independently validated by future outcomes.</li>
<li>Financial position: $665M in cash, asserted runway into early 2028, a 30% year-over-year reduction in operating expenses, and 2026 cash OpEx guidance under $390M, which management says funds near-term milestones without additional financing.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>REC-4881：</strong> 公司報告的 FAP 臨牀概念驗證顯示，前癌性息肉顯著減少，且反應持久，正在與 FDA 進行持續溝通以定義潛在的註冊路徑。</li>
<li><strong>REC-1245（RBM39 降解劑）：</strong> 來自 16 名患者的早期 DAHLIA I 期數據報告沒有劑量限制毒性，PD 確認的靶點參與和 PK 支持每日給藥，預計在下半年將有更多劑量遞增和更全面的 PK/PD 結果。</li>
<li><strong>REC-4539（LSD1 抑制劑）：</strong> 第一名患者在 I 期中接受了該分子的給藥，旨在降低血小板減少症風險，並且能夠穿透大腦；初步的 PK 和安全性數據預計在 2027 年下半年發佈。</li>
<li>平台和模型的進展（TxPert，TxFM）以及公司報告的效率聲明——例如，超過 50PB 的多模態數據，合成化合物減少約 90%，開發候選藥物的進展速度約為 2 倍——正在被應用，但仍需通過未來的結果進行獨立驗證。</li>
<li>財務狀況：現金 665 百萬美元，預計資金可持續到 2028 年初，運營費用同比減少 30%，2026 年現金運營費用指導低於 390 百萬美元，管理層表示這將支持近期里程碑而無需額外融資。</li>
</ul>
</div><h2>Recursion Pharmaceuticals Stock Up 1.3%</h2>
<div class="lb-trans"><h2>Recursion Pharmaceuticals 股票上漲 1.3%</h2>
</div><p>NASDAQ RXRX traded up $0.05 on Wednesday, hitting $3.42. 14,705,881 shares of the company were exchanged, compared to its average volume of 16,692,518. The company has a market cap of $1.80 billion, a PE ratio of -2.31 and a beta of 1.05. Recursion Pharmaceuticals has a 12 month low of $2.80 and a 12 month high of $7.18. The stock has a fifty day moving average of $3.40 and a 200-day moving average of $4.16. The company has a current ratio of 5.50, a quick ratio of 5.50 and a debt-to-equity ratio of 0.01.</p>
<div class="lb-trans"><p>納斯達克 RXRX 週三上漲 0.05 美元，達到 3.42 美元。該公司交易了 14,705,881 股，較其平均交易量 16,692,518 股有所減少。公司的市值為 18 億美元，市盈率為-2.31，貝塔係數為 1.05。Recursion Pharmaceuticals 的 12 個月低點為 2.80 美元，12 個月高點為 7.18 美元。該股票的 50 日移動平均為 3.40 美元，200 日移動平均為 4.16 美元。公司的流動比率為 5.50，速動比率為 5.50，債務與股本比率為 0.01。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><ul>
<li>These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio</li>
</ul>
<div class="lb-trans"><ul>
<li>這些是 NVIDIA 13F 投資組合中唯一的 6 只股票</li>
</ul>
</div><p>A number of research firms have recently commented on RXRX. Wall Street Zen lowered shares of Recursion Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, March 28th. Needham &amp; Company LLC reaffirmed a &#34;buy&#34; rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 26th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 21st. JPMorgan Chase &amp; Co. reduced their price objective on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an &#34;overweight&#34; rating on the stock in a research note on Thursday, April 30th. Finally, Bank of America reduced their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a &#34;neutral&#34; rating on the stock in a research note on Wednesday, February 25th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $9.20.</p>
<div class="lb-trans"><p>多家研究公司最近對 RXRX 發表了評論。華爾街 Zen 在 3 月 28 日的研究報告中將 Recursion Pharmaceuticals 的股票評級從 “持有” 下調至 “賣出”。Needham &amp; Company LLC 在 2 月 26 日的研究報告中重申了 “買入” 評級，並對 Recursion Pharmaceuticals 的股票設定了 8.00 美元的目標價。Weiss Ratings 在 4 月 21 日的研究報告中重申了 Recursion Pharmaceuticals 的 “賣出（d-）” 評級。摩根大通在 4 月 30 日的研究報告中將 Recursion Pharmaceuticals 的目標價從 11.00 美元下調至 10.00 美元，並對該股票設定了 “增持” 評級。最後，美國銀行在 2 月 25 日的研究報告中將 Recursion Pharmaceuticals 的目標價從 7.00 美元下調至 6.00 美元，並對該股票設定了 “中性” 評級。兩位股票研究分析師對該股票給予了 “買入” 評級，兩位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat，Recursion Pharmaceuticals 目前的共識評級為 “持有”，共識目標價為 9.20 美元。</p>
</div><p><strong>Get Our Latest Report on Recursion Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Recursion Pharmaceuticals 的最新報告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人員買賣</h2>
</div><ul>
<li>Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?</li>
</ul>
<div class="lb-trans"><ul>
<li>突然上升：Recursion Pharmaceuticals 是 NVIDIA 的 AI 最愛嗎？</li>
</ul>
</div><p>In related news, Director Blake Borgeson sold 30,000 shares of the stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $3.10, for a total transaction of $93,000.00. Following the transaction, the director directly owned 6,229,863 shares of the company's stock, valued at $19,312,575.30. This represents a 0.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ben R. Taylor sold 13,426 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $3.08, for a total transaction of $41,352.08. Following the transaction, the chief financial officer directly owned 1,195,349 shares in the company, valued at approximately $3,681,674.92. This represents a 1.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 79,680 shares of company stock valued at $256,121 over the last ninety days. 8.43% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事 Blake Borgeson 於 4 月 7 日星期二出售了 30,000 股該股票，交易價格為每股 3.10 美元，總交易額為 93,000.00 美元。交易後，該董事直接持有公司股票 6,229,863 股，價值 19,312,575.30 美元。這代表其持股比例減少了 0.48%。該交易已在證券交易委員會的法律文件中披露，可通過 SEC 網站訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，首席財務官 Ben R. Taylor 於 2 月 18 日星期三出售了 13,426 股該股票，交易價格為每股 3.08 美元，總交易額為 41,352.08 美元。交易後，首席財務官直接持有公司 1,195,349 股，價值約 3,681,674.92 美元。這代表其持股比例減少了 1.11%。該交易的披露信息可在 SEC 文件中找到。在過去 90 天內，內部人員共出售了 79,680 股公司股票，價值 256,121 美元。8.43% 的股票由公司內部人員持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入與流出</h2>
</div><p>Several institutional investors have recently bought and sold shares of RXRX. State Street Corp raised its holdings in shares of Recursion Pharmaceuticals by 38.7% in the fourth quarter. State Street Corp now owns 25,333,888 shares of the company's stock valued at $103,616,000 after purchasing an additional 7,064,963 shares during the last quarter. ARK Investment Management LLC boosted its position in Recursion Pharmaceuticals by 11.2% during the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company's stock worth $152,626,000 after purchasing an additional 3,771,357 shares during the period. Millennium Management LLC bought a new position in Recursion Pharmaceuticals during the fourth quarter worth about $6,118,000. Geode Capital Management LLC boosted its position in Recursion Pharmaceuticals by 13.6% during the fourth quarter. Geode Capital Management LLC now owns 10,934,252 shares of the company's stock worth $44,731,000 after purchasing an additional 1,310,695 shares during the period. Finally, Two Sigma Investments LP boosted its position in shares of Recursion Pharmaceuticals by 109.9% in the third quarter. Two Sigma Investments LP now owns 2,450,805 shares of the company's stock valued at $11,960,000 after acquiring an additional 1,282,992 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者最近買賣了 RXRX 的股票。State Street Corp 在第四季度將其在 Recursion Pharmaceuticals 的持股增加了 38.7%。State Street Corp 目前擁有 25,333,888 股該公司的股票，價值 103,616,000 美元，此前在上個季度又購買了 7,064,963 股。ARK Investment Management LLC 在第四季度將其在 Recursion Pharmaceuticals 的持股增加了 11.2%。ARK Investment Management LLC 目前擁有 37,316,856 股該公司的股票，價值 152,626,000 美元，此前在此期間又購買了 3,771,357 股。Millennium Management LLC 在第四季度購買了 Recursion Pharmaceuticals 的新頭寸，價值約 6,118,000 美元。Geode Capital Management LLC 在第四季度將其在 Recursion Pharmaceuticals 的持股增加了 13.6%。Geode Capital Management LLC 目前擁有 10,934,252 股該公司的股票，價值 44,731,000 美元，此前在此期間又購買了 1,310,695 股。最後，Two Sigma Investments LP 在第三季度將其在 Recursion Pharmaceuticals 的持股增加了 109.9%。Two Sigma Investments LP 目前擁有 2,450,805 股該公司的股票，價值 11,960,000 美元，此前在此期間又收購了 1,282,992 股。機構投資者和對沖基金持有該公司 89.06% 的股票。</p>
</div><h2>Recursion Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Recursion Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Recursion Pharmaceuticals, Inc NASDAQ: RXRX is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals, Inc NASDAQ: RXRX 是一家生物製藥公司，結合了先進的自動化、人工智能和高通量生物學，以發現和開發新型治療藥物。該公司的專有平台將深度學習算法與大規模細胞成像和化學生物學相結合，使得能夠快速識別各種適應症的潛在藥物候選者。通過自動化複雜的實驗室工作流程並利用計算模型，Recursion 旨在加速藥物發現過程並擴大可以解決的靶點範圍。</p>
</div><p>At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.</p>
<div class="lb-trans"><p>Recursion 提供的核心是其數字生物學平台，該平台在不同的化學和遺傳干擾下捕獲數十億個細胞圖像。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Recursion Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Recursion Pharmaceuticals 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlhSWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=RXRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Recursion Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Recursion Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Recursion Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Recursion Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Recursion Pharmaceuticals 並不在名單上。</p>
</div><p>While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Recursion Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Recursion Pharmaceuticals (NASDAQ:RXRX) 公佈季度財務業績